Markets›Health care›BSX

Boston Scientific

BSX
43.92
-0.76 (-1.70%)
Closing price for Sep 25, 2026 from Polygon.io

Valuation

Market value63.65B
Enterprise value75.74B
Price to earnings (P/E)17.8
Price to sales3.0
Price to book2.6
Enterprise value to EBITDA14.2
Free cash flow yield5.7%

Profitability (last 12 months)

Revenue21.00B
Net income3.67B
Gross margin69.9%
Operating margin19.8%
Net margin17.5%
Return on equity14.7%
Return on assets8.1%

Growth (last fiscal year, FY 2025)

Revenue growth+19.9%
EPS growth+55.2%

Balance sheet (latest quarter)

Cash and equivalents539.00M
Total debt12.62B
Debt to equity0.51
Current ratio1.24

Per share and dividends

EPS, diluted (last 12 months)2.47
Shares outstanding1.45B
Dividends paid (last 12 months)None

Trading

Price43.92
52-week high105.65
52-week low42.20
1-year price change-54.74%
Average volume (3 months)20.46M
Beta against the S&P 500 (1 year)0.20

Calculated from Boston Scientific's SEC filings (latest quarter ending Jun 30, 2026) and the price above. "Last 12 months" adds up the four most recent quarters. Beta compares one year of daily returns with the S&P 500 (SPY). Dividends from Polygon.io or Nasdaq.